Sun Pharmaceutical Industries has announced a definitive agreement to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion, marking one of the most significant moves in its global expansion strategy. The deal, priced at $14 per share, will see Sun Pharma take full ownership of Organon, a healthcare company spun off from Merck in 2021.
This acquisition aligns with Sun Pharma’s ambition to strengthen its innovative medicines portfolio while scaling its presence in branded generics and established drugs. Organon’s strong foothold in women’s health, biosimilars, and global markets complements Sun Pharma’s existing capabilities, creating a more diversified and competitive entity.
Post-acquisition, the combined business is expected to rank among the top 25 global pharmaceutical companies, with revenues of approximately $12.4 billion. It will also emerge as a leading player in women’s health and enter the biosimilars segment as a top-tier global contender. With operations spanning over 150 countries, the merged company will significantly expand its commercial reach.
Financially, the deal is projected to enhance cash flows and nearly double EBITDA, enabling faster deleveraging. Sun Pharma plans to fund the acquisition through a mix of internal accruals and bank financing.
Leadership from both companies emphasized the strategic fit, highlighting synergies in product portfolios, global reach, and innovation pipelines. The transaction, approved by both boards, is expected to close in early 2027, subject to regulatory and shareholder approvals.
This move signals Sun Pharma’s intent to evolve into a more innovation-driven, globally integrated pharmaceutical powerhouse.
